ABSTRACT
A novel remote ventilator management (control) technology (Omnitool) was implemented for use with ICU patients during the COVID-19 pandemic to mitigate in-person respiratory therapist interactions and preserve personal protective equipment. In the latter half of 2020, eight mechanical ventilators were purchased and enabled for Omnitool deployment through the application of a vendor software option. Subsequently, these ventilators were outfitted with commercially available informatics hardware that permitted remote communication and management via the existing hospital network. In total, 17 patients with COVID-19 respiratory failure were placed on Omnitool enabled ventilators between January 1, 2021-April 30, 2021. The median Omnitool use days was 10. Deployment of a novel remote ventilator management technology is feasible; however, further study is needed to simplify the set up and utilization of the system. Future demands for remote ventilator management are predictable, whether in rural areas, military scenarios without adequate RT staffing, or in circumstances with new and easily transmissible toxic infections, and will continue to encourage the development of relatively easy to apply informatics-based solutions. Herein we share five lessons learned from our Omnitool deployment.
Subject(s)
COVID-19 , Respiratory Insufficiency , Humans , Pandemics , Ventilators, Mechanical , Respiratory Insufficiency/therapy , TechnologyABSTRACT
Demographics, hospital stay data, and overall outcomes were then reviewed and compared with patients who acquired COVID-19 from the community. The relative uniformity in demographics suggests that all patients admitted to the hospital setting are at risk of infection with COVID-19. Yet little is known about the true incidence of hospital-acquired COVID-19 (HAC), as well as the magnitude of its effect on clinical outcomes. [Extracted from the article] Copyright of Critical Care Medicine is the property of Lippincott Williams & Wilkins and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
ABSTRACT
B Introduction/Hypothesis: b The goal of this study is to assess the utility of remote-controlled ventilator software for routine management that mitigates the need for in-room ventilator interactions with COVID-19 patients. B Results: b 17 patients (F=11, M=6), average age of 62 years, with a median hospital LOS of 37 days, ICU LOS of 30 days, and ventilator days of 25. 11,157 total ventilator interactions (average 656 interactions per patient) were analyzed and categorized. The Omnitool (Medtronic, Minneapolis, MN) software was granted emergency use authorization (EUA) by the Food and Drug Administration for COVID-19 patients only for the duration of the pandemic. [Extracted from the article] Copyright of Critical Care Medicine is the property of Lippincott Williams & Wilkins and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
ABSTRACT
B Introduction/Hypothesis: b The ROX indices offer clinicians an objective assessment of respiratory status while on high flow nasal cannula (HFNC). During the implementation period 12 COVID patients were placed on HFNC, 588 of both ROX indices were calculated and of these there were 262 ROX-HR and 89 ROX scores deemed as critical. [Extracted from the article] Copyright of Critical Care Medicine is the property of Lippincott Williams & Wilkins and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
ABSTRACT
#COVID19-induced ARDS is partly explained by the presence of microthrombi, motivating the use of thrombolytics. This study shows that thrombolytics decrease dead space ventilation in COVID-19 ARDS patients. https://bit.ly/2GdM44a.